NYU Langone Health | Strategic Alliance Partners

The professor of psychiatry and cell biology at NYU Langone provided insight on new findings that uncover the sources of neuronal damage in Alzheimer disease that may explain the failures of antiamyloid therapies.

The professor of psychiatry and cell biology at NYU Langone provided insight on the reaction to a new paper that challenges how traditional drug development has approached Alzheimer disease. [WATCH TIME: 4 minutes]

The associate professor in the Department of Rehabilitation Medicine at NYU Langone discussed a recent study on a new tool aimed at quantifying movements during stroke rehabilitation.

The associate professor in the Department of Rehabilitation Medicine at NYU Langone provided commentary on when the PrimSeq digital tool could see substantial impact on rehabilitation for stroke survivors and other neurological diseases. [WATCH TIME: 4 minutes]

The associate professor in the Department of Rehabilitation Medicine at NYU Langone discussed the current methods of prescribing rehabilitation and why a new digital tool can improve them going forward. [WATCH TIME: 3 minutes]

The associate professor in the Department of Rehabilitation Medicine at NYU Langone provided insight on a recent study that utilized a novel digital tool to track the movement intensity of their stroke rehabilitation. [WATCH NOW: 4 minutes]

The digital tool was used to evaluate more than 12,500 recorded upper body movements among a cohort of 41 adults undergoing poststroke rehabilitation exercises.

Jacqueline A. French, MD, discussed the factors that influence the challenges in treatment selection in epilepsy, and how patient conversations and comprehension of heterogeneity can help in the treatment selection process.

The codirector of Epilepsy Clinical Trials at NYU Langone spoke to the progress that’s been made in treating refractory epilepsy and her hopes for the future of drug development in this area of medicine. [WATCH TIME: 5 minutes]

The professor of neurology at NYU Langone Grossman School of Medicine discussed what high-potential repurposed medications could be an option to treat symptoms of COVID-19 and the realistic possibility of clinical trials. [WATCH TIME: 4 minutes]

The professor of neurology at NYU Langone Grossman School of Medicine broke down the knowns and unknowns about long-term changes related to COVID-19, their legitimacy, and associations with neurodegenerative disorders. [WATCH TIME: 6 minutes]

The professor of neurology at NYU Langone Grossman School of Medicine discussed her talk at AAN 2022 on neurological sequelae and follow-up in hospitalized and nonhospitalized patients with COVID-19. [WATCH TIME: 8 minutes]

Abnormal scores on cognitive testing persisted in 50% of patients without a pre-COVID history of cognitive abnormalities, irrespective of the presence or absence of a neurological complication during hospitalization.

The professor of neurology at the NYU Grossman School of Medicine discussed her presentation at ACTRIMS Forum 2022, which showed better cognitive outcomes in MS following treatment with tDCS. [WATCH TIME: 3 minutes]

The study of 251 hospitalized patients with COVID-19 found that biomarkers were elevated to levels that were similar to—or even higher than—those observed in patients with Alzheimer disease.

The professor of neurology at NYU Langone Grossman School of Medicine discussed future research for neurological complications in patients hospitalized with COVID-19 infection. [WATCH TIME: 4 minutes]

A recent study found that blood markers of brain damage were higher in patients with COVID-19 than in those with Alzheimer disease. [WATCH TIME: 4 minutes]

Jennifer Frontera, MD, professor of neurology, NYU Langone Grossman School of Medicine, discussed findings from a recently published study investigating neurological complications in hospitalized patients with COVID-19.

Patients treated with valbenazine demonstrated favorable outcomes on all secondary outcomes over placebo, as well showed no new safety signals.

The director of the Comprehensive Epilepsy Center at NYU Langone provided closing thoughts on how clinicians can begin to shift gears from research to prevention of SUDEP. [WATCH TIME: 2 minutes]

The director of the Comprehensive Epilepsy Center at NYU Langone discussed the large-scale impact heart rate variability has on preventing SUDEP and the unanswered questions that remain.

The director of the Comprehensive Epilepsy Center at NYU Langone discussed the necessary steps in validating and utilizing heart rate variability as a biomarker for SUDEP. [WATCH TIME: 3 minutes]

Reduced low-frequency power measured at rest was independently associated with an elevated SUDEP risk, presumably through arrhythmogenic mechanisms.

The director of the Comprehensive Epilepsy Center at NYU Langone provided insight on whether a newly discovered biomarker can play a role in the creation of modalities to detect SUDEP risk. [WATCH TIME: 3 minutes]

Ilya Kister, MD, professor of neurology, NYU Grossman School of Medicine, discussed his surprising results from ECTRIMS, which found no evidence of wearing off with ocrelizumab (Ocrevus; Genentech).

The director of the Comprehensive Epilepsy Center at NYU Langone discussed his recently published research, which identified a novel biomarker for sudden unexpected death in epilepsy.

The director of the Comprehensive Epilepsy Center at NYU Langone discussed the critical findings on how heart rate variability may stratify individual SUDEP risk. [WATCH TIME: 4 minutes]

The professor of neurology at the NYU Grossman School of Medicine provided his thoughts on the most notable strides within the multiple sclerosis field in the past year. [WATCH TIME: 3 minutes]